The gene encoding INI1, a component of the mammalian SWI/SNF ATP-dependent chromatin remodeling enzymes, has been classified as a tumor suppressor in humans. Gene-targeting experiments confirmed that Ini1 also functions as a tumor suppressor in mice. Although Ini1-null mice are embryonic lethal, 15-30% of mice heterozygous for Ini1 presented with poorly differentiated tumors with variable rhabdoid features. All tumors examined showed loss of heterozygosity at the Ini1 locus. We report here that cells and tissues heterozygous for the Ini1 tumor suppressor express levels of Ini1 protein and message roughly equivalent to the levels observed in wild type counterparts. Compensation of Ini1 is mediated by an increase in the rate of transcription from the Ini1 promoter. Moreover, when Ini1 is expressed exogenously, transcription from the endogenous promoter is reduced, suggesting that Ini1 levels are tightly regulated. This is the first report describing transcriptional compensation for haploinsufficiency of a tumor suppressor gene.
INI1, a component of the mammalian SWI/SNF ATP-dependent chromatin remodeling enzymes, was first identified as a homologue of the yeast Snf5 protein and as a protein that interacts with the human immunodeficiency virus integrase protein (1, 2) . SWI/SNF chromatin remodeling enzymes use the energy of ATP hydrolysis to alter histone-DNA contacts resulting in an altered nucleosome structure that can lead to repositioning, or sliding, of nucleosomes along the DNA (3) (4) (5) . A consequence of SWI/SNF-mediated chromatin remodeling is increased accessibility of transcriptional regulatory proteins to cognate binding sites on nucleosome particles (6 -9) . The biological relevance of SWI/SNF complexes is evident by the numerous reports indicating that SWI/SNF enzymes positively and negatively regulate gene expression (5, 10, 11) . The role of INI1 in remodeling chromatin and facilitating gene regulation is poorly understood. The ATPase subunits of mammalian SWI/ SNF complexes by themselves exhibit the ability to remodel chromatin in every in vitro assay tested (12) (13) (14) (15) . However, the addition of INI1 and two other SWI/SNF subunits, BAF170 and BAF155, augmented remodeling to levels comparable with that of the purified enzyme complex (12) .
The first evidence implicating INI1 as a tumor suppressor arose when Versteege et al. (16) identified bi-allelic mutations in INI1 in malignant rhabdoid tumors, an aggressive tumor of the soft tissues. Mutations in INI1 were found subsequently in other tumors, such as choroid plexus carcinomas, medulloblastomas, central primitive neuroectodermal tumors, and some cases of leukemia (17) (18) (19) (20) (21) . Identification of constitutional mutations in a subset of these tumors further supported the role of INI1 as a tumor suppressor in humans (22) .
Gene-targeting experiments confirmed that Ini1 functions as a tumor suppressor in mice (23) (24) (25) . Although Ini1-null mice are embryonic lethal, 15-30% of mice heterozygous for Ini1 presented with poorly differentiated tumors with variable rhabdoid features. All tumors examined showed a loss of heterozygosity at the Ini1 locus. Furthermore, almost 100% of mice bearing a reversibly inactivating conditional allele of Ini1 presented rapidly with tumors. The vast majority of these tumors were classified as CD8 ϩ T-cell lymphomas (26) . It is interesting to note the difference in tumor penetrance between Ini1-heterozygous mice and the conditional Ini1 mice. These findings strongly suggest that Ini1 must be lost for tumorigenesis to occur. In contrast, the reduction of p53 protein levels observed in mice heterozygous for the p53 tumor suppressor predisposes the mice to tumor formation without the need for loss of heterozygosity (27) . Where examined, other tumor suppressors, such as caveolin-1, Fhit, T␣R-II (transforming growth factor-␣ type II receptor), and Sno, are similar to p53 in that they also exhibit a marked reduction in protein and/or RNA levels in heterozygous mice (28 -31) .
There are data suggesting that a compensatory mechanism exists to ensure consistent levels of the components of the SWI/SNF complex. In mice deficient for the Brm ATPase subunit of SWI/SNF, the levels of Brg1 protein are increased in several tissues, including the liver, spleen, kidney, brain, lung, heart, and thymus (32) . Up-regulation of Brg1 protein in the Brm-null mice is believed to account for the lack of severe phenotype in these mice. Furthermore, when HeLa cells were transfected with an a hemagglutinin-tagged BRM construct, BRG1 protein levels decreased as detected by indirect immunofluorescence (32) . These findings suggest that a balance of BRG1 and BRM protein levels must be maintained in mammalian organisms. In addition, expression of a mutant BAF57, another SWI/SNF subunit, in transgenic mice suppresses the levels of endogenous BAF57 protein (33) . Therefore, the absence of cancer and the apparent requirement for loss of heterozygosity in tumorigenesis in the Ini1 haploinsufficient tissues might be explained if Ini1 is up-regulated in the Ini1-heterozygous mice.
We report here that cells and tissues heterozygous for the Ini1 tumor suppressor express levels of Ini1 protein and message that are nearly equivalent to the levels observed in wild type (WT) 1 counterparts. We further show that the rate of transcription from the Ini1 promoter is increased in Ini1-heterozygous cells, accounting for the increase in steady state message levels. Moreover, we find that exogenous expression of Ini1 results in a decrease in expression from the endogenous Ini1 promoter, suggesting that Ini1 plays a role in the regulation of its own promoter. In summary, the findings reported here indicate that expression of the Ini1 gene is tightly regulated, possibly to maintain proper levels of this important developmental regulator and tumor suppressor.
EXPERIMENTAL PROCEDURES
Cells-Embryonic stem (ES) cells containing a retroviral promoter trap that functionally inactivates one Ini1 allele were previously described (25, 34) . Mouse embryo fibroblasts (MEFs) from wild type or Ini1-heterozygous mouse embryos were prepared and cultured according to standard procedures.
mRNA Analyses-RNA from indicated tissues and cells was isolated in Trizol (Invitrogen) following the manufacturer's protocol. Reverse transcription was performed using random hexamers and Mu-MLV RT (Invitrogen) with 2 g of RNA for each sample. In Figs. 2 and 3, Ini1 levels were amplified using the primers 5Ј-gcgtcaagtttcagctggagg-3Ј (sequence from exon 1) and 5Ј-catgcggttcctgttgatggtggt-3Ј (sequence from exon 4). The real-time PCR data presented in Fig. 4 used the reverse primer 5Ј-caccagcacctcaggctgtgacgc-3Ј for Ini1 amplification (sequence from exon 5). ␤-Actin was amplified using primers 5Ј-gcttctttgcagctccttcgttg-3Ј and 5Ј-tttgcacatgccggagccgttgt-3Ј. GAPDH was amplified using the primers 5Ј-gcagtggcaaagtggagattgt-3Ј and 5Ј-cacggccatcacgccacagctt-3Ј. 18 S rRNA was amplified using primers 5Ј-acttggataactgtggtaattc-3Ј and 5Ј-aattaccgcggctgctggcacc-3Ј. For Figs. 2 and 3, Ini1 and ␤-actin PCR reactions were performed for 24 cycles using HotStart Taq and MasterMix (Qiagen) supplemented with [ For Northern blots, 10 g of RNA from each sample was electrophoresed on a formaldehyde gel and transferred to GeneScreen plus membranes. Hybridization was performed with a radiolabeled probe consisting of exons 1-5 from the Ini1 cDNA at 50°C in 10% dextran sulfate, 1.5ϫ SSPE (saline/sodium phosphate/EDTA), and 1% SDS, 0.5% milk, and 625 g/ml yeast RNA extract. Blots were washed twice for 20 min with 1% SDS, 2ϫ SSC at 50°C, and then washed once for 15 min with 1% SDS and 0.2ϫ SSC at 50°C.
For mRNA half-life studies, cells were grown to 80% confluency prior to the addition of 10 g/ml actinomycin D (Sigma). Cells were harvested at 2-h intervals between 0 and 12 h after the addition of actinomycin D and again for a final time point at 24 h. Sample amplifications were carried out by real-time PCR (MJ Research) using Qiagen SYBR-green reagents to determine the linear range for each primer set. Results shown are the average of two experiments performed in triplicate for each time point. Wild type levels at time 0 were arbitrarily set to 1, and the remaining time points were adjusted accordingly.
Nuclear Run-on Assay-Nuclear run-on transcription assays as described by Schü beler and Bode 2 were carried out. NaOH and EDTA were added to linearized Bluescript SK plasmids containing cDNAs corresponding to exons 1-3 of Ini1, full-length GAPDH, or no insert as a control to a final concentration of 0.4 and 10 mM, respectively. Samples were boiled for 10 min, chilled, dot-blotted in 2-l aliquots to GeneScreen plus membranes, and cross-linked via Stratalinker. Prehybridization was carried out for at least 2 h at 60°C in 1% SDS, 10% dextran sulfate, 1.4 M NaCl, and 325 g/ml each of salmon sperm DNA and yeast RNA extract. Equivalent amounts of run-on RNA (ϳ3 ϫ 10 6 counts/min) from WT and Ini1-heterozygous cell extracts were added to the blot and hybridized for 16 -42 h. Blots were washed as described by Schü beler and Bode. 2 Western Analyses-Extracts from indicated tissues and cells were isolated as described previously (25) . Forty-five to fifty micrograms of each sample were used for Western analysis as described (25, 35) . Antibodies against Ini1, Brg1, Brm, and tubulin have been described previously (25, 35) . Antibody against phosphatidylinositol 3-kinase was purchased from Upstate Biotech. Determination of relative protein levels was accomplished by scanning multiple film exposures and quantifying them in ImageQuant (Amersham Biosciences).
␤-Galactosidase Assays-FuGENE reagent (Roche Applied Science) was used to transfect BOSC23 cells (36) with either a retroviral pBABE vector or a pBABE vector encoding a FLAG epitope-tagged INI (37), both of which were modified to carry a blasticidin resistance gene. Briefly, the blasticidin resistance gene was amplified by PCR from pEM7/Bsd (Invitrogen) and cloned into pGEM-T-Easy (Promega). The blasticidin resistance gene was then excised with ClaI and HindIII, purified via GeneClean III (Bio 101), and cloned into ClaI/HindIIIrestricted pBABE-CeINI1 (37) or pBABE to replace the existing puromycin resistance gene. After 48 h, the transfected BOSC cell supernatants were used to infect Ini1-heterozygous mouse embryonic fibroblasts at 80% confluence. Forty-eight hours after infection, blasti- cidin (10 g/ml) was added to the mouse embryonic fibroblasts to select for infected cells. After 48 h of selection, ␤-galactosidase assays were performed using the Promega ␤-galactosidase enzyme assay system with reporter lysis buffer.
RESULTS AND DISCUSSION

Tissues and Cells Heterozygous for Ini1 Contain Levels of Ini1 Protein and mRNA That are Nearly Equivalent to Levels
Present in WT Tissues and Cells-We previously generated mice heterozygous for Ini1 using an inactivating retroviral insertion vector (25) . The targeted allele is interrupted by the insertion between exons 3 and 4 ( Fig. 1 and see Ref. 25 ). The ␤-galactosidase-neomycin resistance gene fusion cassette contains a 5Ј splice acceptor site; thus the Ini1 promoter at the targeted locus drives expression of a fusion protein that consists of the first three exons of Ini1 fused to the ␤-galactosidaseneomycin fusion. In addition, exons 4 -9 of Ini1 are transcribed as a fusion with the puromycin resistance gene product under the control of the PGK promoter but are not translated. All PCR-based detection of Ini1 mRNA levels in this study used primer sets in which products span the insertion site and therefore detect only mRNA from the intact, nontargeted allele.
During the characterization of Ini1-heterozygous mice, we observed that various tissues from the heterozygotes contained levels of Ini1 mRNA that were approximately equivalent to those from WT tissues (Fig. 2, data not shown) . We next looked at the levels of Ini1 protein and message in WT and Ini1-heterozygous mouse ES cells and MEFs. Fig. 3A shows a Western blot of the levels of the SWI/SNF components Ini1, Brg1, and Brm present in these cells. The levels of Ini1 protein appeared to be equivalent whether there were one or two functional copies of the Ini1 locus. Brg1 and Brm levels were not affected by the loss of one Ini1 allele. Consistent with previous results, Brm protein was not present at detectable levels in ES cells (38) . To better quantify Ini1 protein levels in WT and heterozygous cells, protein samples were run next to a titration of extract (Fig. 3B) . The experiment demonstrates that the intensity of the bands is within the linear range of protein detection and that Ini1 protein levels are not reduced 2-fold in the heterozygous cell lines as might be expected from the inactivation of one Ini1 allele but instead are nearly equivalent.
To examine mRNA levels in WT and Ini1-heterozygous cell lines, we performed a Northern blot as well as RT-PCR. Levels of Ini1 mRNA in heterozygous cells were similar to levels in WT cells (Fig. 3C) . Although the Northern blot has the potential to distinguish the fusion mRNAs from the targeted allele, the individual mRNAs can be distinguished from each other and from WT Ini1 mRNA on the basis of size. The Northern blot results were subsequently confirmed using RT-PCR (Fig. 3D) . Quantification of the Western, Northern, and RT-PCR experiments consistently indicated that the levels of Ini1 mRNA and protein in Ini1-heterozygous MEFs were 80 -90% of those present in WT MEFs, and the levels of Ini1 mRNA and protein in Ini1-heterozygous ES cells were 110 -125% of those present in WT ES cells.
Compensation of Ini1 Levels in Ini1-heterozygous Cells Is Accomplished at the Level of Transcription
Initiation-We hypothesized that compensation of Ini1 mRNA levels might be achieved by either an increase in the stability of Ini1 mRNA or an increase in the rate of transcription from the Ini1 promoter. To compare the relative half-life of Ini1 mRNA in WT and Ini1-heterozygous MEF cells, cultures were treated with actinomycin D and harvested at various intervals until 24 h. Ini1 and GAPDH mRNA decay was monitored by real-time PCR. The decay rate of Ini1 message in Ini1-heterozygous cells was equivalent to that in WT cells (Fig. 4) , indicating that Ini1 compensation is not mediated by an increase in Ini1 mRNA stability.
We next examined the rate of transcription of Ini1 in WT and Ini1-heterozygous MEF cells via run-on transcription assay. Newly synthesized RNA from WT and Ini1-heterozygous cells was radiolabeled and used to probe cDNAs immobilized on a membrane. As described above and previously (25) , Ini1-heterozygous cells contain one wild type allele of Ini1 as well as an allele of Ini1 that is disrupted by the insertion of a retroviral vector within intron 3. This insertion results in the synthesis of a fusion transcript containing exons 1-3 of Ini1 fused to ␤-galactosidase under the control of the endogenous Ini1 promoter. Thus, a plasmid containing Ini1 cDNA corresponding to exons 1-3 was used in this experiment to identify only those transcripts generated from the Ini1 promoter. A plasmid containing GAPDH cDNA and an empty plasmid vector served as controls. Ini1-heterozgous cells contained roughly double the amount of radiolabeled Ini1 RNA as did WT cells (Fig. 5) . If compensation were not occurring at the level of transcription, we would have expected equivalent signals in WT and Ini1-heterozygous cells because the WT cells would have produced mRNA containing Ini1 exons 1-3 from both alleles, whereas the Ini1-heterozygous cells also would have produced mRNA containing Ini1 exons 1-3 from both the WT and targeted alleles. The results therefore demonstrate the occurrence of transcriptional compensation at the Ini1 promoter.
Exogenous Ini1 Expression Down-regulates Ini1 Promoter Activity-Because the rate of transcription from the Ini1 promoter is increased in cells containing one functional Ini1 allele, we asked whether exogenously expressed Ini1 would decrease the amount of transcription from the Ini1 promoter. We utilized the fact that the targeted Ini1-heterozygous cells contain a ␤-galactosidase gene cassette under the control of the Ini1 promoter (Ref. 25 and see Fig. 1 ) and monitored the activity of the Ini1 promoter in Ini1-heterozygous MEFs infected with a retrovirus encoding FLAG-tagged Ini1 or with the empty retroviral vector. Examination of cell lysate from infected cells clearly shows that the exogenous FLAG-tagged Ini1 was expressed; however, reprobing the blot for total Ini1 protein levels revealed that the overall increase in Ini1 protein levels was less than 2-fold (Fig. 6A) . The cells infected with Ini1 exhibited reduced ␤-galactosidase activity as compared with cells infected with empty vector (Fig. 6B) . The reduction in ␤-galactosidase activity was ϳ1.5-fold, in good agreement with the -fold overexpression of Ini1 protein. Thus, the cells are sensitive to the amount of Ini1 present and compensate both positively and negatively to maintain appropriate levels of Ini1 mRNA and protein.
Transcriptional Compensation for Loss of a Tumor Suppressor Allele-In mammals, few cases involving a compensatory increase in the levels of transcription on loss of one gene copy have been documented (39) , perhaps because any phenotypic differences that might occur because of haploinsufficiency may not be observed in heterozygous individuals if the targeted gene were up-regulated. However, such compensation might be advantageous to prevent the loss of gene products affecting cell proliferation. Numerous reports have linked Ini1 function to control of cell cycle (40 -44) . Additionally, whereas 15-30% of Ini1-heterozygous mice present with tumors, almost 100% of mice bearing a reversibly inactivating conditional allele of Ini1 do so (26) . The difference in tumor penetrance between Ini1-heterozygous mice and the conditional Ini1 mice and the correlation between loss of heterozygosity and tumor presentation in Ini1-heterozygous mice strongly suggest that Ini1 must be lost for tumorigenesis to occur. It is possible that the observed transcriptional compensation for Ini1 heterozygosity contributes to the low tumor penetrance in Ini1-heterozygous mice, because the increase in transcription rate from the single functional allele may prevent potentially deleterious effects resulting from decreased levels of Ini1 protein.
An additional consideration for why cells might compensate for loss of one Ini1 allele would be to maintain stoichiometric levels of each of the components comprising a multisubunit enzyme. To date none of the mammalian SWI/SNF subunits except for BAF53 is known to exist in cells either independently or as part of different protein complexes (45) . Maintenance of equivalent concentrations of multiple gene products each encoded by different genes would likely be complex and require a "sensing" mechanism to determine the relative levels of each protein and to trigger a regulatory response, positively or negatively, should the levels of one protein vary. Presently, much of the evidence for cross-talk between SWI/SNF subunits pertains to that between BRG1 and BRM, the two related ATPases (32) . However, the existing biochemical studies have shown that BRG1 and BRM form distinct enzyme complexes (9), which may suggest a level of cross-talk that maintains the relative levels of the different enzymes. This may be a regulatory problem that is distinct from maintaining equivalent levels of subunits in the same enzyme complex. The mechanism(s) by which the expression of Ini1, BRG1, BRM, and other SWI/ SNF subunit genes are regulated in response to altered levels of their own gene product or the protein levels of other subunits remain to be determined.
It is important to note that the observed compensation in Ini1 levels does not appear to be exact. We consistently observed levels of Ini1 mRNA and protein in Ini1-heterozygous MEFs that were 10 -20% lower than those in WT MEFs, whereas the levels of Ini1 mRNA and protein in Ini1-heterozygous ES cells were 10 -25% higher than those in WT ES cells. The implication is that an individual heterozygous for Ini1 may still be susceptible to the consequences of Ini1 misregulation.
